Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients — APPE

Ovarian Response Clinical Trial

Official title:
hCG Priming Prior to COH in Poor Responder IVF Patients

Status Completed

Clinical Trial Summary

There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging. Recent evidence suggest that testosterone or DHEA may improve ovarian response in poor prognosis patients by increasing intraovarian androgen concentration. A physiological way to induce androgen synthesis within the ovary is to stimulate theca cells androgen production by hCG stimulation. By doing this in the previous cycle we might expect a better response to COH.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Ovarian Response

Clinical Trial Details

NCT number	NCT00870025
Study type	Interventional
Source	IVI Madrid
Contact
Status	Completed
Phase	Phase 4
Start date	October 2008
Completion date	September 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00693108` - Androgens for Poor Responders in In Vitro Fertilization	Phase 3
Completed	`NCT04168892` - Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response
Completed	`NCT00844350` - The Effect of Oxytocin (OT) and Oxytocin Plus Human Chorionic Gonadotropin (hCG), in Cycles Induced by Letrozole or Clomiphene Citrate	Phase 2